Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6539)	6/11/2002 6:48:36 PM
From: sammaster	Read Replies (2) \| Respond to of 52153

biotech valuations i think are nearing at least their short term lows as this now feels like a capitulation selloff where the longtimers on many threads are giving up hope whereas in the past they would buy on the dips.... chartwise naz support at 1100 and btk support at 300... so which biotechs/pharmas have the most value now in the threads opinion? my picks so far pending further research(there are so many long term bargains out there) ELN lots of current and near term products, also lots of uncertainties with accounting MLNM lots of cash, 1 current product, large pipeline but very distant drug candidates SEPR 1 drug, lots of near term potential drugs but lots of debt VICL lots of cash, low cash burn, possible very useful drug delivery platform, but no near term drugs with huge potential also looking at GENZ,ITMN,SCIO,ICOS any other ideas and short reasons why?

To: Biomaven who wrote (6539)	6/12/2002 6:36:28 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

As I said here just yesterday: Some repurchases by the first-tier biotechs would probably be a good thing here. AMGN has done this for years to good effect. Guess they must be reading this thread as well: <g> Wednesday June 12, 5:10 pm Eastern Time Press Release SOURCE: Amgen Amgen Announces $2 Billion Stock Repurchase Plan THOUSAND OAKS, Calif., June 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN - News), the world's largest biotechnology company, today announced that its Board of Directors has authorized an additional repurchase of up to $2 billion in Amgen common stock through June 30, 2004. The company has approximately $260 million remaining under a previous stock repurchase program. In 2002, Amgen has repurchased 18.4 million shares or approximately $1 billion of its common stock. "The current valuation of Amgen stock makes repurchases of Amgen stock a solid investment and represents an attractive opportunity to enhance long-term shareholder value," said Kevin Sharer, Amgen's Chairman and Chief Executive Officer. Stock is up in after-hours. Peter